Shasun Pharmaceuticals is currently trading at Rs. 80.40, up by 0.60 points or 0.75% from its previous closing of Rs. 79.80 on the BSE.
The scrip opened at Rs. 80.90 and has touched a high and low of Rs. 82.70 and Rs. 79.95 respectively. So far 67318 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 91.50 on 24-Feb-2012 and a 52 week low of Rs. 38.10 on 16-Dec-2011.
Last one week high and low of the scrip stood at Rs. 91.50 and Rs. 75.00 respectively. The current market cap of the company is Rs. 393.94 crore.
The promoters holding in the company stood at 46.73% while Institutions and Non-Institutions held 16.45% and 36.83% respectively.
Shasun Pharmaceuticals has received an offer from Caduceus Asia Mauritius (CAML), an investment arm of US-based OrbiMed, a global healthcare-dedicated investment firm to invest Rs 50 crore into the company at a share price of Rs 76 per share. This would translate into an 11.93% stake for the new investor post allotment.
Proceeds from the issue would be used to part finance the ongoing capital expenditure plans of the company for FY13, which includes building a new manufacturing facility in Vizag.
OrbiMed’s two-decade experience with pharma and life sciences companies will be very helpful in shaping our strategic road map.
Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: